Jimmy Yuen
Overview
Explore the profile of Jimmy Yuen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
429
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yau T, Cheng P, Chan P, Chen L, Yuen J, Pang R, et al.
Invest New Drugs
. 2015 Feb;
33(2):496-504.
PMID: 25666409
This study was designed to evaluate the efficacy, safety profile, pharmacokinetics, pharmacodynamics and quality of life of pegylated recombinant human arginase 1 (Peg-rhAgr1) in patients with advanced hepatocellular carcinoma (HCC)....
2.
Yau T, Cheng P, Chan P, Chan W, Chen L, Yuen J, et al.
Invest New Drugs
. 2012 Mar;
31(1):99-107.
PMID: 22426640
Background: Hepatocellular carcinoma (HCC) cells are auxotrophic for arginine, depletion of which leads to tumour regression. The current study evaluated safety, pharmacokinetics (PK)/ pharmacodynamics (PD) parameters, and potential anti-tumor activity...
3.
Lam V, Ng K, Chok K, Cheung T, Yuen J, Tung H, et al.
J Am Coll Surg
. 2008 Jul;
207(1):20-9.
PMID: 18589357
Background: Local recurrence rates after radiofrequency ablation (RFA) of hepatocellular carcinoma (HCC) vary from 2% to 36% in the literature. Limited data were available about the prognostic significance of local...
4.
Lam V, Ng K, Chok K, Cheung T, Yuen J, Tung H, et al.
Ann Surg Oncol
. 2007 Dec;
15(3):782-90.
PMID: 18095030
Background: Complete ablation rates after a single session of radiofrequency ablation (RFA) of hepatocellular carcinoma (HCC) vary from 48% to 97%. Limited data are available regarding risk factors and prognostic...
5.
Khan M, Poon R, Ng K, Chan A, Yuen J, Tung H, et al.
Arch Surg
. 2007 Dec;
142(12):1136-43.
PMID: 18086979
Hypothesis: Radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC) can be performed by percutaneous or surgical approach. Tumor size is an important consideration while deciding the treatment approach. Design: Case series...
6.
Chan F, Ng K, Poon R, Yuen J, Tso W, Fan S
Asian J Surg
. 2007 Oct;
30(4):278-82.
PMID: 17962132
Radiofrequency ablation (RFA) is a treatment option in the management of unresectable or recurrent hepatocellular carcinoma (HCC). It can be performed either through laparotomy or in a minimally invasive manner...
7.
Ng K, Poon R, Lo C, Yuen J, Tso W, Fan S
J Gastrointest Surg
. 2007 Sep;
12(1):183-91.
PMID: 17874276
Background: Radiofrequency ablation (RFA) is an effective local ablation therapy for hepatocellular carcinoma (HCC) with favorable long-term outcome. There is no data on the analysis of recurrence pattern and its...
8.
Poon R, Lau C, Pang R, Ng K, Yuen J, Fan S
Ann Surg Oncol
. 2007 Apr;
14(6):1835-45.
PMID: 17406950
Background: Radiofrequency ablation (RFA) is a recently developed treatment for hepatocellular carcinoma (HCC). Thus far, the prognostic impact of tumor biomarkers has not been evaluated in this treatment. High serum...
9.
Chok K, Ng K, Poon R, Ming Lam C, Yuen J, Tso W, et al.
Arch Surg
. 2006 Dec;
141(12):1231-6.
PMID: 17178966
Hypothesis: The survival benefits of radiofrequency ablation (RFA) and transarterial chemoembolization (TACE) are similar for patients with unresectable hepatocellular carcinoma amenable to either treatment. Design: Retrospective comparative study. Setting: Tertiary...
10.
Chow D, Sinn L, Ng K, Ming Lam C, Yuen J, Fan S, et al.
J Surg Oncol
. 2006 Oct;
94(7):565-71.
PMID: 17048238
Background: This study compared the effectiveness of radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC) and liver metastases. Methods: We compared the outcomes of 240 patients with HCC and 44 patients...